Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03465722 · ClinicalTrials.gov registry record · Phase 3
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
A Phase 3 study of GIST, sponsored by Blueprint Medicines Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 476
- Enrollment target
- 20
- Study locations
NCT03465722 is a Phase 3 study of GIST that has completed, run by Blueprint Medicines Corporation. The registered enrollment target is 476 participants, above the 77-participant average among 8 other GIST trials with a reported enrollment target (518% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT03465722, a Phase 3 study of GIST, has completed, sponsored by Blueprint Medicines Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 476 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with imatinib and 1 or 2 other TKIs.
Conditions Studied
Interventions
- DRUG regorafenib
- DRUG avapritinib
Study Locations (20)
Florida
- Mayo Clinic Cancer Center - Jacksonville
- University of Miami - Miami
- Moffitt Cancer Center - Tampa
Colorado
- University of Colorado Hospital - Aurora
- Rocky Mountain Cancer Centers - Boulder
Illinois
- Northwestern Medicine - Chicago
- The University of Chicago Medical Center - Chicago
Arizona
- Mayo Clinic Cancer Center - Phoenix
California
- UCLA Hematology/Oncology - Santa Monica - Santa Monica
District of Columbia
- Washington Hospital Center - Oncology and Hematology - Washington D.C.
Georgia
- Northside Hospital - Atlanta
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 476 participants |
| Start Date | 2018-03-26 |
| Est. Completion | 2021-09-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03465722
The ClinicalTrials.gov registry entry for NCT03465722 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 476 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 77-participant average among 8 other GIST trials with a reported enrollment target (518% higher). The listed sponsor is Blueprint Medicines Corporation, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with GIST appearing as the primary indexed condition, and to 2 interventions - of which regorafenib is the first listed.
NCT03465722 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, Colorado, Illinois.
Frequently Asked Questions
What is clinical trial NCT03465722 about?
NCT03465722 is a clinical study titled "(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST". This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with imatinib and 1 or 2 other TKIs.
What is the current status of trial NCT03465722?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 476 participants. The study started on 2018-03-26. Estimated completion is 2021-09-15.
What conditions does trial NCT03465722 study?
This clinical trial studies the following conditions: GIST.
What interventions are being tested in trial NCT03465722?
The interventions under investigation include: regorafenib (DRUG), avapritinib (DRUG).
Who is sponsoring clinical trial NCT03465722?
This trial is sponsored by Blueprint Medicines Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03465722 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for GIST
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
ACTIVE NOT RECRUITING · Phase 3
-
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
RECRUITING · Phase 1
-
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
RECRUITING · Phase 1
-
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
ACTIVE NOT RECRUITING · Phase 2
-
Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
ACTIVE NOT RECRUITING · Phase 2
-
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.